1. Home
  2. GWRS vs IKT Comparison

GWRS vs IKT Comparison

Compare GWRS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Water Resources Inc.

GWRS

Global Water Resources Inc.

HOLD

Current Price

$7.26

Market Cap

203.9M

Sector

Utilities

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

HOLD

Current Price

$1.91

Market Cap

220.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GWRS
IKT
Founded
2003
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Water Supply
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
203.9M
220.5M
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
GWRS
IKT
Price
$7.26
$1.91
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$9.20
$5.00
AVG Volume (30 Days)
124.0K
596.7K
Earning Date
05-13-2026
03-26-2026
Dividend Yield
4.22%
N/A
EPS Growth
N/A
57.76
EPS
N/A
N/A
Revenue
$41,914,000.00
N/A
Revenue This Year
$15.29
N/A
Revenue Next Year
$8.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
8.51
N/A
52 Week Low
$6.55
$1.33
52 Week High
$11.17
$2.26

Technical Indicators

Market Signals
Indicator
GWRS
IKT
Relative Strength Index (RSI) 58.89 67.45
Support Level $7.19 $1.63
Resistance Level $7.81 $1.91
Average True Range (ATR) 0.25 0.08
MACD 0.04 0.03
Stochastic Oscillator 97.32 92.31

Price Performance

Historical Comparison
GWRS
IKT

About GWRS Global Water Resources Inc.

Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix and Tucson, Arizona. It operates within the State of Arizona. Operating revenue of the company is derived from regulated water, wastewater, and recycled water service provided to customers based upon tariff rates.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: